Effects of LIraglutide on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Type II diabetes is a known risk factor for heart failure, particularly through the
progressive development of diabetic cardiomyopathy. Cardiac metabolic parameters, including
myocardial steatosis and epicardial fat, are altered in diabetic patients. The development of
new anti-diabetics (incretins) has demonstrated protective cardiovascular effects independent
of effects on glycemic control for the first time in the history of these therapies. Thus
Glucagon-Like Peptide 1 (GLP-1) agonists improve the recovery of cardiac function after a
heart attack and decrease atheromatous processes. It has also been demonstrated in a diabetic
rat model that the administration of Liraglutide, a GLP-1 agonist, leads to normalization of
myocardial steatosis associated with beneficial cardiac molecular remodeling involving
pro-apoptotic, oxidative and metabolic processes. These beneficial cardiovascular effects
were observed in the absence of any changes in blood glucose, insulin levels or body weight.